Jones Financial Companies
GRCE

Jones Financial Companies’s Grace Therapeutics GRCE Stock Holding History

Jones Financial Companies’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-29
Closed -$86 – 4402
2025
Q2 		$86 Buy
+29
New +$77 ﹤0.01% 3958

Other funds holding GRCE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MFA
Millington Financial Advisors Naperville, Illinois $237M AUM 22.22% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return

Jones Financial Companies's GRCE Position: Q3 2025 in Review

Jones Financial Companies sold out of Grace Therapeutics (GRCE) in Q3 2025, closing a stake of 29 shares — an estimated $86 sold.

Jones Financial Companies first reported a position in GRCE in Q2 2025 and held it in 1 quarter. The position peaked at $86 in Q2 2025. 20 funds tracked by Wall St. Rank hold GRCE as of Q3 2025.

  • Jones Financial Companies reported no remaining Grace Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Jones Financial Companies sold 29 Grace Therapeutics shares in Q3 2025, an estimated $86.
  • Jones Financial Companies first reported a position in Grace Therapeutics in Q2 2025 and held it in 1 quarter.
  • Jones Financial Companies's Grace Therapeutics position peaked at $86 in Q2 2025.
  • 20 funds tracked by Wall St. Rank held Grace Therapeutics as of Q3 2025.

Based on Jones Financial Companies's 13F filing for Q3 2025, filed 4 Nov 2025.